

# Résultats 2021

Felix Burkhardt, CFO


Assemblée générale, 11 mai 2022

Galenica – La santé et le bien-être nous tiennent à cœur.




# Croissance exceptionnelle en 2021

Chiffre d'affaires net (en mio. CHF)



Initiatives  
COVID-19  
+3.1%



Forte croissance du  
chiffre d'affaires  
dans le domaine des  
maladies rares

**MEDI SERVICE**  
Apothek Farmacia Farmacie



M&A




Nouvelles parts de  
marché gagnées  
dans le commerce  
de gros auprès des  
médecins



# Prévisions du chiffre d'affaires 2022


en mio. CHF




**Chiffre d'affaires net du Groupe Galenica 2022 au moins au niveau de l'année précédente**

# Résultat record en 2021

**EBIT ajusté<sup>2)</sup>** (en mio. CHF)



**Initiatives  
COVID-19<sup>1)</sup>**  
CHF 25 mio.




**Vente  
immeuble du  
siège**  
CHF 9.4 mio.



- 1 L'Impact des initiatives de COVID-19 inclut le chiffre d'affaires net des tests PCR, des tests rapides antigéniques, des autotests ainsi que des vaccinations; impact EBIT estimé
- 2 Hors effets IAS19 et IFRS16, voir Rapport annuel 2021, chapitre «Alternative performance measures»

# Prévisions pour l'EBIT 2022

en mio. CHF



2021

2022


- Initiatives de COVID-19
- Vente immeuble du siège
- Affaires ordinaires

**EBIT ajusté<sup>1)</sup> de 5% à +10%, hors les résultats extraordinaires des initiatives COVID-19 (CHF 25 mio.) et la vente de l'immeuble du siège (CHF 9.4 mio.)**

<sup>1</sup> Hors effets IAS19 et IFRS16, voir Rapport annuel 2021, chapitre «Alternative performance measures»

# Investissements dans l'avenir

en mio. CHF



en % du chiffre d'affaires net 1.6%

1.6%

## Investissements en immobilisations incorporelles:

- Implémentation SAP chez Alloga/Galexis
- Infrastructure numérique chez Galenica pour le programme Omni-channel

---


## Investissements en immobilisations corporelles :

- Rénovation du centre logistique d'Ecublens
- Rénovation des pharmacies

# Bilan solide

en mio. CHF

- Fonds propres ajustés<sup>1)</sup>
- Endettement net ajusté<sup>1)</sup>



Debt coverage ajusté<sup>2)</sup>


1.7x

1.0x

1 Détails relatifs aux ajustements dans le Rapport annuel 2021, chapitre «Alternative performance measures»

2 Endettement net ajusté / EBITDA ajusté (hors effets IAS 19 et IFRS 16), Rapport annuel 2021, chapitre «Alternative performance measures»

# Dividende: augmentation forte et durable du dividende



**Prévision du dividende 2022:  
au moins au niveau de 2021**

1 Selon proposition à l'Assemblée générale du 11 mai 2022  
2 Dividende par action par rapport au cours boursier à la date du bilan



A toute allure sur la bonne voie



# Disclaimer

## **Disclaimer Galenica**

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

## **Disclaimer IQVIA**

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third-party sources or data. In all cases where historical results are presented or past performance is described, we note that past performance is not a reliable indicator of future results and performance.

Copyright ©2022 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.